T1	Participants 69 120	218 patients with a median follow-up of eight years
T2	Participants 428 488	218 patients with previously untreated HD entered this study
T3	Participants 276 407	patients with advanced stage Hodgkin's disease (HD), as well as in early stage patients with systemic symptoms and/or bulky disease
